{"id":112047,"date":"2026-08-27T08:25:13","date_gmt":"2026-08-27T08:25:13","guid":{"rendered":"https:\/\/www.europesays.com\/britain\/112047\/"},"modified":"2026-08-27T08:25:13","modified_gmt":"2026-08-27T08:25:13","slug":"astrazeneca-drug-succeeds-in-trial-for-swallowing-disorder-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/britain\/112047\/","title":{"rendered":"AstraZeneca drug succeeds in trial for swallowing disorder"},"content":{"rendered":"

\"AstraZeneca<\/a> AstraZeneca drug succeeds in trial for swallowing disorder Proactive uses images sourced from Shutterstock <\/p>\n

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN)<\/a> said its drug Tezspire worked in a late-stage trial of patients with eosinophilic esophagitis, a chronic condition that inflames the gullet and makes swallowing difficult. <\/p>\n

The drug, developed with the American biotech company Amgen, hit both of its main goals and every important secondary one. <\/p>\n

The trial, called CROSSING, involved 368 patients aged between 12 and 80 who were still suffering symptoms despite existing treatment. <\/p>\n

They were given either a low dose of Tezspire, a high dose, or a placebo, injected under the skin every four weeks. <\/p>\n

Both doses reduced inflammation in the gullet and eased difficulty swallowing compared with the placebo at 24 weeks, and the benefit lasted through to 52 weeks. <\/p>\n

AstraZeneca said side effects were broadly in line with what has already been seen in approved uses of the drug. <\/p>\n

The company has not yet released the underlying numbers, which will be presented at a medical conference and given to regulators. <\/p>\n

The condition affects more than 470,000 people in the United States, and cases have risen fivefold since 2009. <\/p>\n

Almost half of patients do not get adequate relief from current first-line options, which include steroids, acid-suppressing drugs and restricted diets. <\/p>\n

Left untreated, it can cause food to become stuck in the gullet, sometimes requiring emergency treatment. <\/p>\n

Tezspire is already approved for severe asthma in more than 70 countries and for a form of chronic sinus disease in the United States, Europe, China and Japan. <\/p>\n

It works by blocking a protein released by the lining of the airways and gut that triggers inflammation. <\/p>\n

More than 100,000 patients have been treated with it since 2021. <\/p>\n","protected":false},"excerpt":{"rendered":"AstraZeneca drug succeeds in trial for swallowing disorder Proactive uses images sourced from Shutterstock AstraZeneca PLC (LSE:AZN, NASDAQ:AZN)…\n","protected":false},"author":2,"featured_media":112048,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20662],"tags":[11153,38873,2718],"class_list":["post-112047","post","type-post","status-publish","format-standard","has-post-thumbnail","category-astrazeneca","tag-astrazeneca","tag-biotech-company","tag-patients"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/117166520962631326","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/112047","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=112047"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/112047\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/112048"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=112047"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=112047"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=112047"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}